Understanding of chronic atrophic gastritis "inflammation-cancer transformation" based on turbidity theory
-
摘要: 慢性萎缩性胃炎“炎-癌转化”是胃癌发生的重要途径。国医大师李佃贵教授创新提出浊毒理论，并系统阐述了浊毒的内涵、浊毒的物质形态、浊毒形成的原因。同时基于浊毒理论深入阐明慢性萎缩性胃炎“炎-癌转化”的邪正盛衰及病机演变过程，针对不同阶段的病机特点辨证论治，形成了系统的证治体系，拓宽了认识慢性萎缩性胃炎“炎-癌转化”的新思路。Abstract: Chronic atrophic gastritis "inflammatory-cancer transformation" is an important way of gastric cancer occurrence. Professor LI Diangui, a master of Traditional Chinese Medicine, innovatively put forward the theory of turbidity poison, and systematically elaborated the connotation of turbidity poison, the substance form of turbidity poison, and the reasons for the formation of turbidity poison. At the same time, based on the turbidity theory, the evolution process of chronic atrophic gastritis, according to the syndrome differentiation and treatment of different stages, formed a systematic evidence and treatment system, and broadened the new idea of understanding the "inflammatory-cancer transformation" of chronic atrophic gastritis.
-
-
[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. doi: 10.3322/caac.21492
[2] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[3] Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. doi: 10.1016/S0140-6736(19)30427-1
[4] 杜奕奇, 蔡全才, 廖专, 等. 中国早期胃癌筛查流程专家共识意见(草案)(2017年, 上海)[J]. 胃肠病学, 2018, 23(2): 92-97. doi: 10.3969/j.issn.1008-7125.2018.02.007
[5] Pellicano R. Is chronic atrophic gastritis the missing link between atrophic glossitis, gastric parietal cell antibody positivity and hematological deficiencies?[J]. J Formos Med Assoc, 2020, 119(5): 1004-1005. doi: 10.1016/j.jfma.2020.01.003
[6] Madhav D, Umesha B, Sachin S, et al. Narrow band imaging for detection of gastric intestinal metaplasia and dysplasia: A systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2021, 36(8): 2038-2046. doi: 10.1111/jgh.15564
[7] 王晓瑜, 徐艳, 吴云林. 胃癌前病变逆转的中西医治疗探讨[J]. 国际消化病杂志, 2020, 40(6): 367-370. doi: 10.3969/j.issn.1673-534X.2020.06.003
[8] 李园, 赵莹, 陈萌, 等. 从中医学视角探讨慢性胃炎"炎癌转化"过程的免疫失衡与重建[J]. 北京中医药大学学报, 2021, 44(1): 92-96. https://www.cnki.com.cn/Article/CJFDTOTAL-JZYB202101014.htm
[9] Elinav E, Nowarski R, Thaiss CA, et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms[J]. Nat Rev Cancer, 2013, 13(11): 759-771. doi: 10.1038/nrc3611
[10] Baniyash M, Sade-Feldman M, Kanterman J. Chronic inflammation and cancer: suppressing the suppressors[J]. Cancer Immunol Immunother, 2014, 63(1): 11-20. doi: 10.1007/s00262-013-1468-9
[11] Janssen WJ, Henson PM. Cellular regulation of the inflammatory response[J]. Toxicol Pathol, 2012, 40(2): 166-173. doi: 10.1177/0192623311428477
[12] Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability[J]. Carcinogenesis, 2009, 30(7): 1073-1081. doi: 10.1093/carcin/bgp127
[13] Candido J, Hagemann T. Cancer-related inflammation[J]. J Clin Immunol, 2013, 33(Suppl 1): S79-S84.
[14] Song XD, Wang YN, Zhang AL, et al. Advances in research on the interaction between inflammation and cancer[J]. J Int Med Res, 2020, 48(4): 300060519895347.
[15] 张桂贤, 刘洪斌, 刘大卫. 非可控性炎症与肿瘤相关性研究[J]. 中国中西医结合外科杂志, 2015, 21(2): 197-201. doi: 10.3969/j.issn.1007-6948.2015.02.034
[16] Jia R, Guo X, Liu H, et al. Analysis of Staged Features of Gastritis-Cancer Transformation and Identification of Potential Biomarkers in Gastric Cancer[J]. J Inflammation Res, 2022, 15: 6857-6868. doi: 10.2147/JIR.S390448
[17] 张丹, 刘伟, 田雯, 等. 健脾化瘀解毒方抑制细胞焦亡防治胃癌前病变的机制[J]. 中华中医药杂志, 2022, 37(5): 2831-2835. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY202205076.htm
[18] 李君秋, 喻晓, 潘洁露, 等. 基于"久病入络"理论探析胃癌前病变的发病机制[J]. 安徽中医药大学学报, 2022, 41(5): 15-18. https://www.cnki.com.cn/Article/CJFDTOTAL-AHZY202205005.htm
[19] 李志云, 王捷虹, 杨燕燕, 等. 沈舒文辨治胃癌前病变临床经验采撷[J]. 吉林中医药, 2022, 42(4): 408-412. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJL202204009.htm
[20] 黄岩, 谢晶日. 谢晶日从"治中焦如衡"论治胃癌前病变[J]. 中医药导报, 2021, 27(9): 180-182. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZB202109040.htm
[21] 王东鑫, 梁广和, 高志远, 等. 徐湘江教授治疗胃癌前病变经验[J]. 中医临床研究, 2022, 14(18): 114-116. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYLY202218036.htm
[22] 卫静静, 李京尧, 赵蓓蓓, 等. 论肾对胃癌前病变截断扭转的重要性及治疗策略[J]. 中华中医药杂志, 2020, 35(10): 5064-5067. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY202010083.htm
[23] 李佃贵. 中医浊毒论[M]. 北京: 人民卫生出版社, 2016: 6-13.
[24] 赵润元, 刘小发. 李佃贵国医大师从浊毒论治脾胃病临床体悟[J]. 世界中西医结合杂志, 2018, 13(3): 335-337, 373. https://www.cnki.com.cn/Article/CJFDTOTAL-SJZX201803011.htm
[25] 孙建慧, 杨倩, 刘阳, 等. 构建中医浊毒理论体系框架的思考[J]. 中医杂志, 2020, 61(8): 660-663. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ202008006.htm
[26] 刘小发, 刘建平, 杜艳茹, 等. 李佃贵从浊毒论治慢性萎缩性胃炎伴肠上皮化生[J]. 环球中医药, 2016, 9(11): 1299-1302. https://www.cnki.com.cn/Article/CJFDTOTAL-HQZY201611005.htm
[27] 刘小发, 李佃贵, 姜建明, 等. 基于辩证唯物主义的浊毒理论发病观、治疗观和发展观[J]. 河北中医, 2022, 44(12): 1941-1944. https://www.cnki.com.cn/Article/CJFDTOTAL-HBZY202212001.htm
[28] 徐伟超, 李佃贵, 刘建平, 等. 浊毒理论创新中医病因病机学[J]. 中国中西医结合杂志, 2019, 39(8): 913-915. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ201908011.htm
[29] 丁霞, 魏玮, 沈洪, 等. 从中医学视角看慢性胃炎"炎-癌转化"[J]. 北京中医药大学学报, 2018, 41(11): 885-889. https://www.cnki.com.cn/Article/CJFDTOTAL-JZYB201811001.htm
[30] 吴俊琦. 治未病、传统保健体育与"健康中国"建设[J]. 辽宁中医药大学学报, 2019, 21(11): 204-206. https://www.cnki.com.cn/Article/CJFDTOTAL-LZXB201911057.htm
-
计量
- 文章访问数: 733
- PDF下载数: 300
- 施引文献: 0
下载: